Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1998 1
2002 1
2003 1
2004 1
2005 4
2006 5
2007 7
2008 3
2009 3
2011 2
2012 2
2014 1
2017 1
2018 1
2019 2
2022 4
2023 11
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Results by year

Filters applied: . Clear all
Page 1
Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial.
Danese S, Vermeire S, D'Haens G, Panés J, Dignass A, Magro F, Nazar M, Le Bars M, Lahaye M, Ni L, Bravata I, Lavie F, Daperno M, Lukáš M, Armuzzi A, Löwenberg M, Gaya DR, Peyrin-Biroulet L; STARDUST study group. Danese S, et al. Among authors: lavie f. Lancet Gastroenterol Hepatol. 2022 Apr;7(4):294-306. doi: 10.1016/S2468-1253(21)00474-X. Epub 2022 Feb 1. Lancet Gastroenterol Hepatol. 2022. PMID: 35120656 Clinical Trial.
Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study.
Schett G, Chen W, Gao S, Chakravarty SD, Shawi M, Lavie F, Zimmermann M, Sharaf M, Coates LC, Siebert S. Schett G, et al. Among authors: lavie f. Arthritis Res Ther. 2023 Aug 16;25(1):150. doi: 10.1186/s13075-023-03125-4. Arthritis Res Ther. 2023. PMID: 37587493 Free PMC article. Clinical Trial.
Improvement in patient-reported outcomes and work productivity following 3-year ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: results from the PsABio real-world study.
Gossec L, Siebert S, Bergmans P, de Vlam K, Gremese E, Joven-Ibáñez B, Korotaeva TV, Lavie F, Noël W, Nurmohamed MT, Sfikakis PP, Sharaf M, Theander E, Smolen JS. Gossec L, et al. Among authors: lavie f. Arthritis Res Ther. 2023 Jun 23;25(1):109. doi: 10.1186/s13075-023-03058-y. Arthritis Res Ther. 2023. PMID: 37353788 Free PMC article.
Clinical trial: Clinical and endoscopic outcomes with ustekinumab in patients with Crohn's disease: Results from the long-term extension period of STARDUST.
Peyrin-Biroulet L, Vermeire S, D'Haens G, Panés J, Dignass A, Magro F, Nazar M, Le Bars M, Lahaye M, Ni L, Bravatà I, Lavie F, Daperno M, Lukáš M, Armuzzi A, Löwenberg M, Gaya DR, Danese S. Peyrin-Biroulet L, et al. Among authors: lavie f. Aliment Pharmacol Ther. 2024 Jan;59(2):175-185. doi: 10.1111/apt.17751. Epub 2023 Nov 30. Aliment Pharmacol Ther. 2024. PMID: 38036946 Clinical Trial.
Earlier clinical response predicts low rates of radiographic progression in biologic-naïve patients with active psoriatic arthritis receiving guselkumab treatment.
Mease PJ, Gottlieb AB, Ogdie A, McInnes IB, Chakravarty SD, Rampakakis E, Kollmeier A, Xu XL, Shawi M, Lavie F, Kishimoto M, Rahman P. Mease PJ, et al. Among authors: lavie f. Clin Rheumatol. 2024 Jan;43(1):241-249. doi: 10.1007/s10067-023-06745-y. Epub 2023 Oct 3. Clin Rheumatol. 2024. PMID: 37787903 Free PMC article. Clinical Trial.
Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: results from a phase 3, randomised, double-blind, placebo-controlled study of biologic-naïve patients with active psoriatic arthritis.
Gottlieb AB, McInnes IB, Rahman P, Kollmeier AP, Xu XL, Jiang Y, Sheng S, Shawi M, Chakravarty SD, Lavie F, Mease PJ. Gottlieb AB, et al. Among authors: lavie f. RMD Open. 2023 Feb;9(1):e002789. doi: 10.1136/rmdopen-2022-002789. RMD Open. 2023. PMID: 36828643 Free PMC article. Clinical Trial.
The development of a preliminary ultrasonographic scoring system for features of hand osteoarthritis.
Keen HI, Lavie F, Wakefield RJ, D'Agostino MA, Hammer HB, Hensor E, Pendleton A, Kane D, Guerini H, Schueller-Weidekamm C, Kortekaas MC, Birrel F, Kloppenburg M, Stamm T, Watt I, Smolen JS, Maheu E, Dougados M, Conaghan PG. Keen HI, et al. Among authors: lavie f. Ann Rheum Dis. 2008 May;67(5):651-5. doi: 10.1136/ard.2007.077081. Epub 2007 Aug 17. Ann Rheum Dis. 2008. PMID: 17704062 Review.
Hurdles in new drug development in rheumatic diseases.
Lavie F, Rooney T. Lavie F, et al. Joint Bone Spine. 2023 Nov 30;91(4):105672. doi: 10.1016/j.jbspin.2023.105672. Online ahead of print. Joint Bone Spine. 2023. PMID: 38042361 Free article.
Pharmacotherapy (excluding biotherapies) for ankylosing spondylitis: development of recommendations for clinical practice based on published evidence and expert opinion.
Lavie F, Pavy S, Dernis E, Goupille P, Cantagrel A, Tebib J, Claudepierre P, Flipo RM, Le Loët X, Maillefert JF, Mariette X, Saraux A, Schaeverbeke T, Wendling D, Combe B. Lavie F, et al. Joint Bone Spine. 2007 Jul;74(4):346-52. doi: 10.1016/j.jbspin.2007.04.003. Epub 2007 May 30. Joint Bone Spine. 2007. PMID: 17590370 Review.
44 results